Manufacturing process of dendritic cell therapy

 

​

Production is customized for each patient (“autologous”).

Each step is precisely defined and monitored by quality controls.

​

1. Blood collection from the patient

Approximately 150–180 ml of whole blood or leukapheresis (depending on the procedure) is collected.

Objective: to obtain monocytes—the precursor cells of dendritic cells.

​

2. Isolation of monocytes

In the GMP laboratory, the monocytes are separated from the rest of the blood under sterile conditions.

​

3. Differentiation into dendritic cells

The cells are cultivated in a special nutrient solution and transform into immature dendritic cells within several days.

​

4. Loading with tumor antigens

This is where the therapy becomes individualized:

• Tumor lysate

• Neoantigens

• Defined proteins or peptides

The DCs receive a kind of biological “identity card” of the tumor in order to specifically alert the immune system to the cancer cells.

​

5. Maturation into activated dendritic cells

The cells are stimulated to develop a highly active immunological profile – important for a strong T-cell response.

​

6. Quality controls

Each batch is tested for:

• Sterility

• Purity

• Cell count

• Viability

• Functional activity

Only flawless preparations are released.

​

7. Injection into the patient

The finished dendritic cells are injected intradermally or subcutaneously.

They present the tumor antigens to the T cells — the start of a targeted immune response.

Why GMP is so important for patients

​

Protection against contamination or foreign substances

• Consistent quality of every cell therapy

• Safety in the manufacture of individualized drugs

• Independent laboratory testing and regulatory monitoring

• Traceability of every production step

Dendritic cell therapy without GMP standards would not be medically or legally permissible.

GMP and IMMUMEDIC

​

IMMUMEDIC works exclusively with GMP-certified European laboratories that specialize in immunological cell therapies.

As a result, all DC preparations manufactured comply with the European guidelines for ATMPs (Advanced Therapy Medicinal Products).

Our claim:

Highest quality, maximum safety, and individually tailored therapy for each patient.

​

Legal notice – No promise of healing

The procedures described on this website, in particular the manufacture and application of autologous dendritic cell therapy, are for medical information and education purposes.

 

They are not a substitute for medical advice, diagnosis, or therapy recommendations.

 

Dendritic cell therapy and other immunological procedures are patient-specific treatment approaches whose effectiveness depends on numerous biological factors.

Therefore, no promise of healing or guarantee of treatment success can be derived from the information presented.

 

Neither IMMUMEDIC Limited nor the cooperating laboratories, physicians, or clinics make any assurances regarding:

• therapeutic success,

• tumor regression,

• symptom improvement,

• prolongation of life,

• or the effectiveness of individual complementary measures.

 

All assessments of a possible therapy option are based on the available medical records and the individual health status of the patient.

 

The decision on treatment is always made by the responsible medical professional.

For further questions, we recommend a personal consultation with qualified specialists.